Scarica l'app Stockscreener
0.6449
12.18%
0.07
Dopo l'orario di chiusura:
.61
-0.0349
-5.41%
Precedente Chiudi:
$0.5749
Aprire:
$0.5857
Volume 24 ore:
1.28M
Relative Volume:
1.97
Capitalizzazione di mercato:
$6.84M
Reddito:
$1.85M
Utile/perdita netta:
$-5.56M
Rapporto P/E:
-0.8505
EPS:
-0.7583
Flusso di cassa netto:
-
1 W Prestazione:
-25.83%
1M Prestazione:
-51.87%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.5448
$0.68
Intervallo di 1 settimana:
$0.538
$0.989
Portata 52W:
$0.538
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Nome
20 20 Biolabs Inc
Settore
Industria
Telefono
(240) 453-6339
Indirizzo
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.6449 | 6.32M | 1.85M | -5.56M | 0 | -0.7583 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc Borsa (AIDX) Ultime notizie
AIDX - Finviz
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Trending Stocks Today | Aspire Biopharma up 6.03% Post-Market - Moomoo
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
20/20 Biolabs (AIDX) Surges 10.86%: Key Levels and Market SentimentETF AUM Growth - newsline.com
20/20 Biolabs (AIDX) Dips 7.75% – Key Support Test in FocusFactor Crowding - newsline.com
20/20 Biolabs (AIDX) Slumps 7.75% as Stock Nears Key $0.76 Support LevelFactor Rotation - newsline.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
20/20 Biolabs (NASDAQ: AIDX) asks shareholders to raise authorized shares to 500M - Stock Titan
20/20 Biolabs, Inc. Files Form 8-K Announcing Amended and Restated Bylaws and Nasdaq Listing as Emerging Growth Company - Minichart
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters - The Manila Times
20/20 Biolabs' OneTest™ Selected for Vermont Firefighter Cancer Screening Initiative, Expected to Generate $500,000 in Revenue - Quiver Quantitative
20/20 Biolabs, Inc.Common Stock (Nasdaq:AIDX) Stock Quote - The Chronicle-Journal
20/20 Biolabs (NASDAQ: AIDX) cuts quorum for shareholder meetings - Stock Titan
No Analysis Provided - StocksToTrade
AIDX Slides As 20/20 Biolabs Inc. Faces Heavy Selling - timothysykes.com
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand - Sahm
Maxim Group Maintains 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained - TipRanks
AIDX Stock Slides As 20/20 Biolabs Tests Key Support - timothysykes.com
20/20 Biolabs stock surges on Ebola testing plans By Investing.com - Investing.com Australia
20/20 Biolabs stock surges on Ebola testing plans - Investing.com India
20/20 Biolabs Engages Pcr Test Kit Developers For Ebola And Hantavirus Testing - TradingView
20/20 Biolabs Commences Emergency Planning for Ebola & - GlobeNewswire
20/20 Biolabs 2Q Loss/Shr 28c >AIDX - Moomoo
20/20 Biolabs (NASDAQ: AIDX) registers 10.105M shares; posts Q1 2026 results - Stock Titan
McLean telehealth company seeks to raise $17.25M in IPO - The Business Journals
20/20 Biolabs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
20/20 Biolabs (AIDX) posts lower Q1 revenue and deeper loss after $5M preferred raise - Stock Titan
20/20 BioLabs reports Q1 2026 revenue $0.4M, net loss $2.17M, cash $4.2M - TradingView
Q1 2026: 20/20 BioLabs (AIDX) revenue declines as cash rises on $5M raise - Stock Titan
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - The Manila Times
Press Release: 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - Moomoo
20/20 Biolabs, Inc. 1Q 2026: Revenue $353.38K, EPS ($0.28) — 10-Q Summary - TradingView
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout
Maxim Group Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
20/20 Biolabs (AIDX) delays 10-Q filing; expects 5-day extension - Stock Titan
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Number of shareholders of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 - GlobeNewswire
AIDX | 20/20 Biolabs, Inc. Common FinancialsIncome Statement - Quiver Quantitative
USC inks licensing agreement for prostate cancer screening tool - University of South Carolina
20/20 BioLabs Licenses Patented Algorithm from University of South Carolina for Early Detection of Aggressive Prostate Tumors - Quiver Quantitative
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina - The Manila Times
New PSA algorithm uses repeat blood tests to flag high-risk prostate tumors early - Stock Titan
20 20 Biolabs Inc Azioni (AIDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):